Form 4: Fortress Biotech Director Receives Restricted Stock Grant

Fortress Biotech director Malcolm Hoenlein received a grant of 27,322 restricted shares, vesting over three years, with a portion deferred into share units.

Summary

• Director Malcolm Hoenlein was granted 27,322 shares of restricted common stock of Fortress Biotech, Inc. (FBIO).
• The grant was made on January 1, 2026, pursuant to the Issuer's 2013 Stock Incentive Plan, as amended.
• The restricted shares will vest in three equal installments, with one-third vesting on January 1, 2027, January 1, 2028, and January 1, 2029, subject to continued service.
• Hoenlein elected to defer 25% of these restricted shares into deferred share units (DSUs) under the Issuer's Deferred Compensation Plan for Directors, subject to the same vesting conditions.
• Vested deferred shares will be delivered to the reporting person in January of the year following termination of service, or earlier upon their death or a change in control of the Issuer.
• Following this transaction, Hoenlein beneficially owns a total of 115,747 shares, which includes 52,507 shares underlying deferred restricted stock units.

Sentiment

Score: 7

Explanation: This is a routine compensation filing for a director, indicating standard corporate governance practices. It aligns director incentives with shareholder interests, which is a positive, but does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The grant of restricted stock aligns the director's interests with those of shareholders, promoting long-term commitment and performance.
• The multi-year vesting schedule encourages continued service and stability in the board of directors, fostering long-term strategic oversight.

Negatives

• The issuance of new shares, even restricted, can lead to minor dilution for existing shareholders over time as they vest.

Risks

• The vesting of restricted shares is contingent on the director's continued service, meaning the shares could be forfeited if service terminates prematurely.
• The value of the granted shares is tied to the future stock price of Fortress Biotech, Inc., exposing the director to market risk.

Future Outlook

The future outlook involves the vesting of the granted restricted shares and deferred share units over the next three years, contingent on the director's continued service. Vested deferred shares will be delivered post-termination or upon specific events like death or change in control.

Industry Context

Equity grants, particularly restricted stock with multi-year vesting, are a common form of compensation for directors in the biotechnology and broader corporate sectors. This practice aims to align the interests of directors with long-term shareholder value creation, a standard governance practice across industries.

Comparison to Industry Standards

• The use of restricted stock grants with multi-year vesting for director compensation is a widely accepted practice in corporate governance, consistent with compensation strategies observed in comparable biotech companies.
• This approach is designed to incentivize long-term commitment and performance, aligning with best practices for non-executive director remuneration across various industries.

Corporate Governance

Related Party Transactions

• The grant of restricted stock and deferred share units to Director Malcolm Hoenlein constitutes a related party transaction, as it involves compensation provided by the issuer to a member of its board of directors. This is a standard practice for director remuneration.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of shares, but improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Continued service of Malcolm Hoenlein as a director.
• Vesting of one-third of the restricted shares and deferred share units on January 1, 2027.
• Vesting of one-third of the restricted shares and deferred share units on January 1, 2028.
• Vesting of the final one-third of the restricted shares and deferred share units on January 1, 2029.
• Delivery of vested deferred share units to the reporting person in January of the year following termination of service, or earlier upon death or change in control.

Key Dates

Recommendation

This Form 4 filing details a routine grant of restricted stock to a director as part of their compensation package. It does not contain any new operational, financial, or strategic information that would warrant a change in investment recommendation. The grant aligns director incentives with long-term shareholder value, which is a positive for governance, but it is not a catalyst for significant price movement. Therefore, a 'hold' recommendation is appropriate as existing investment theses remain unchanged.

Keywords

Fortress Biotech, FBIO, Form 4, restricted stock, equity grant, director compensation, stock incentive plan, deferred compensation, beneficial ownership